Hasil Pencarian - Benoit You

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses

    Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses oleh Amine Souadka, Hajar Essangri, Mohammed Anass Majbar, Amine Benkabbou, Saber Boutayeb, Benoit You, Olivier Glehen, Raouf Mohsine, Naoual Bakrin

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10Research in context

    Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in... oleh Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma

    Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma oleh Constance Collet, Jonathan Lopez, Christophe Battail, Fabienne Allias, Mojgan Devouassoux-Shisheboran, Sophie Patrier, Nicolas Lemaitre, Touria Hajri, Jérôme Massardier, Benoit You, François Mallet, François Golfier, Nadia Alfaidy, Pierre-Adrien Bolze

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

    First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study oleh Anne-Claire Hardy-Bessard, Fabien Brocard, Florian Clatot, Alain Lortholary, Benoît You, Julien Grenier, Jérôme Martin-Babau, Brigitte Lucas, Jérôme Meunier, Jean-Marc Ferrero, Aude-Marie Savoye, Adina Marti, Raymond Despax, Isabelle Moullet, George Emile

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

    Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody oleh Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients

    The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients oleh Benoit You, Frédéric Mercier, Eric Assenat, Carole Langlois-Jacques, Olivier Glehen, Julien Soulé, Léa Payen, Vahan Kepenekian, Marie Dupuy, Fanny Belouin, Eric Morency, Véronique Saywell, Maud Flacelière, Philippe Elies, Pierre Liaud, Thibault Mazard, Delphine Maucort-Boulch, Winston Tan, Bérengère Vire, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert, Alexandre Prieur

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study oleh Magali Rebucci-Peixoto, Magali Rebucci-Peixoto, Angélique Vienot, Angélique Vienot, Angélique Vienot, Olivier Adotevi, Olivier Adotevi, Olivier Adotevi, Marion Jacquin, Marion Jacquin, Francois Ghiringhelli, Christelle de la Fouchardière, Benoit You, Tristan Maurina, Elsa Kalbacher, Fernando Bazan, Guillaume Meynard, Anne-Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Dewi Vernerey, Dewi Vernerey, Aurélia Meurisse, Aurélia Meurisse, Stefano Kim, Stefano Kim, Stefano Kim, Christophe Borg, Christophe Borg, Christophe Borg, Laura Mansi

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: